Form 4: Sutro Biopharma Director Heidi Hunter Acquires Stock Options

Director Heidi Hunter acquired stock options in Sutro Biopharma, Inc. on June 6, 2024.

Summary

• On June 6, 2024, Heidi Hunter, a director of Sutro Biopharma, Inc., acquired stock options to purchase 35,000 shares of common stock.
• The exercise price of these options is $3.76 per share.
• The options vest monthly starting July 6, 2024, and will be fully vested by the earlier of the 2025 annual stockholders meeting or June 6, 2025, contingent upon continued service to the issuer.
• The options expire on June 6, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock option grants, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the options is tied to the director's continued service.

Industry Context

This filing is a routine disclosure related to insider transactions and provides limited insight into broader industry trends. However, it reflects the compensation practices common in the biotechnology industry, where stock options are frequently used to incentivize executives and directors.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech industry.
• The vesting schedule and exercise price are typical for such grants, aligning the director's interests with those of the shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates